High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Status:
Completed
Trial end date:
2021-04-21
Target enrollment:
Participant gender:
Summary
High-dose chemotherapy and autologous stem cell transplantation (ASCT) as part of the
up-front treatment of patients with multiple myeloma has been associated with improved
disease-free and overall survival in multiple large randomized controlled trials. Following
3-6 cycles of standard induction therapy with biologic agents, consolidation with high dose
Melphalan and ASCT has become the standard-of-care approach for fit myeloma patients up to 70
years of age. Single-agent high-dose Melphalan (200mg/m2) is currently the standard-of-care
preparative regimen prior to autologous transplant in Myeloma. Historical studies utilizing
Busulfan- or Total Body Irradiation-based preparative regimens have yielded similar results
to single-agent Melphalan with higher toxicity.